Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06199934 · ClinicalTrials.gov registry record
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 19,853,610
- Enrollment target
NCT06199934: Completed study, sponsored by Pfizer.
NCT06199934 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 19,853,610 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06199934 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 19,853,610 participants
- Enrollment target
Study Summary
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.
Primary Outcome
Number of participants diagnosed with COVID-19 were reported in this outcome measure.
Interventions
- BIOLOGICAL Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,853,610 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-07-31 |
What the finished NCT06199934 record still lists
NCT06199934 is an observational study that tracks outcomes without assigning an intervention. Its 19,853,610 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Vaccination is the first listed.
NCT06199934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06199934 about?
NCT06199934 is a clinical study titled "Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data". The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgen...
What is the current status of trial NCT06199934?
This trial is currently completed. The enrollment target is 19,853,610 participants. The study started on 2023-09-11. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT06199934?
The interventions under investigation include: Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT06199934?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02485847 · 20,000,000 participants
IRIS Registry: Intelligent Research in Sight Registry
- NCT05678699 · 10,000,000 participants · NA
The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI